Physician profile
Kara Travis Mudd
NPI 1730374794
$98,164.23
in general payments reported to CMS, 2019-2025
31 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,386 · 2022: $1,722 · 2023: $17K · 2024: $36K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Consulting Fee: $16K · Food and Beverage: $13K · Travel and Lodging: $3,508 · Honoraria: $2,800 · Education: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,384.50 |
| Consulting Fee | $16,375.50 |
| Food and Beverage | $12,574.38 |
| Travel and Lodging | $3,508.00 |
| Honoraria | $2,800.00 |
| Education | $414.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $35,601.35 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $19,210.09 | 2021-2025 | Dupixent |
| Incyte Corporation | $10,811.41 | 2021-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $6,921.67 | 2023-2024 | Tapinarof, Vtama |
| Ucb, INC. | $4,508.67 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $3,108.81 | 2022-2025 | Adbry, Anzupgo |
| Organon LLC | $2,956.09 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $2,878.91 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,994.89 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Abbvie INC. | $1,848.45 | 2021-2025 | |
| Janssen Biotech, INC. | $1,813.70 | 2021-2025 | Tremfya |
| Regeneron Pharmaceuticals, INC. | $1,719.36 | 2025 | Dupixent |
| Biofrontera INC. | $1,126.61 | 2021-2022 | |
| Almirall LLC | $666.24 | 2022-2025 | Klisyri, Seysara |
| Lilly USA, LLC | $569.22 | 2021-2025 | Taltz, Ebglyss, Olumiant |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.86 | 2021 | |
| Amgen INC. | $362.33 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $348.42 | 2021-2025 | Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $330.52 | 2023-2025 | Zoryve |
| Pfizer INC. | $291.05 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $164.74 | 2023-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Mayne Pharma Commercial LLC | $72.55 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.48 | 2021-2024 | Cabtreo |
| Allergan, INC. | $35.69 | 2021 | |
| Dermira, INC. | $29.04 | 2021 | |
| Nabriva Therapeutics, Plc | $27.65 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $22.22 | 2024 | Nuzyra |
| Vyne Pharmaceuticals INC. | $16.33 | 2021 | |
| Sebela Pharmaceuticals INC. | $15.71 | 2023 | Naftin, Pramosone |
| Epi Health, LLC | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Mudd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.